We have witnessed weight loss of 13–15% with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and up to 18–23% with the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) ...

Suzhou-based Innovent Biologics secured approval last week for its treatment mazdutide. Read more at straitstimes.com. Read ...

Ozempic, the diabetes drug that's also used for weight loss, has a few scary side effects. This is according to reports that were raised during a recent American Psychiatric Association (APA) meeting.

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

Novo Nordisk just killed its deal with Hims & Hers. But Hims might come out stronger after this development. Read why the ...

The MHRA has revealed it's received more than 560 reports of acute pancreatitis in patients taking GLP-1 injections since ...

China NMPA approves Innovent’s mazdutide, first dual GCG/GLP-1 receptor agonist for chronic weight management: San Francisco, US Monday, June 30, 2025, 12:00 Hrs [IST] Innovent ...

Suzhou-based Innovent Biologics Inc. secured approval last week for its treatment mazdutide ... the emergence of a viable local alternative to Novo and Lilly’s blockbuster GLP-1 treatments could make ...

Blockbuster weight-loss shots like Ozempic, Wegovy and Victoza may have an unexpected side effect impacting as many as ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone. Ozempic for blood sugar control and Wegovy for weight loss both use different ...

"It's criminal to put someone on a GLP-1 and not put them on a dietary plan," says Phil Vella, founder of Vita Bella Clinics, ...

People with unresponsive chronic migraine and obesity experienced substantial relief after they started taking a GLP-1 drug, ...